1222010-52-7

Upstream product

• 773097-04-4 2-(2-bromo-4-fluorophenyl)-1,3-dioxolane 
• 1226773-35-8 C₁₆H₁₅BrO₃ 
• 1226773-36-9 (5-(benzyloxy)-2-formylphenyl)boronic acid 
• 1222010-47-0 6-benzyloxy-1,3-dihydro-1-hydroxy-2,1-benzoxaborole 
• 59142-68-6 2-bromo-4-fluorobenzaldehyde 
• 229027-89-8 (2-bromo-4-fluorophenyl)methanol 
• 1222010-85-6 2-((4-(benzyloxy)-2-bromobenzyl)oxy)tetrahydro-2H-pyran 
• 1222010-84-5 2-((2-bromo-4-fluorobenzyl)oxy)tetrahydro-2H-pyran 
• 1196473-37-6 6-hydroxyl-1,3-dihydro-1-hydroxy-2,1-benzoxaborole 
• 103-71-9 phenyl isocyanate 

Relevant academic research and scientific papers

Design, synthesis, and structure-activity relationship of trypanosoma brucei leucyl-tRNA synthetase inhibitors as antitrypanosomal agents

African trypanosomiasis, caused by the proto zoal pathogen Trypanosoma brucei (T. brucei), is one of the most neglected tropical diseases that are in great need of new drugs. We report the design and synthesis of T. brucei leucyl-tRNA synthetase (TbLeuRS) inhibitors and their structure-activity relationship. Benzoxaborole was used as the core structure and C(6) was modified to achieve improved affinity based on docking results that showed further binding space at this position. Indeed, compounds with C(7) substitutions showed diminished activity due to clash with the eukaryote specific I4ae helix while substitutions at C(6) gave enhanced affinity. TbLeuRS inhibitors with IC 50 as low as 1.6 μM were discovered, and the structure-activity relationship was discussed. The most potent enzyme inhibitors also showed excellent T. brucei parasite growth inhibition activity. This is the first time that TbLeuRS inhibitors are reported, and this study suggests that leucyl-tRNA synthetase (LeuRS) could be a potential target for antiparasitic drug development.

BORON-CONTAINING SMALL MOLECULES AS ANTI-PROTOZOAL AGENTS

This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.

Discovery of novel benzoxaborole-based potent antitrypanosomal agents

We report the discovery of benzoxaborole antitrypanosomal agents and their structure?activity relationships on central linkage groups and different substitution patterns in the sulfur-linked series. The compounds showed in vitro growth inhibition IC5